Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Donanemab: What is the new Alzheimer’s drug rejected for use on the NHS
Donanemab: Everything we know about the latest Alzheimer’s drug rejected by the NHS - Donanemab and another new drug for Alzheimer’s called Lecanemab have been billed as a huge step forward in researc
Donanemab – what we know about the latest Alzheimer’s drug
Donanemab can slow the progression of Alzheimer’s disease.But what is the drug and how does it work? Here your questions on the latest development in Alzheimer’s research are answered.– What kind of treatment is Donanemab?
U.K.’s cost-effectiveness agency says Alzheimer’s drug donanemab does not provide good value
For the second time in recent months, a U.K. agency said the limited benefits of a new Alzheimer’s drug do not justify its costs.
NICE rejects Donanemab for NHS use despite MHRA approval
Donanemab marks a significant advancement in Alzheimer’s treatment, but NHS patients face a setback with NICE's rejection of its cost-effectiveness.
New Alzheimer’s treatment donanemab does not currently demonstrate value for the NHS says NICE
Donanemab (also called Kisunla and made by Eli Lilly) has been licensed today by the MHRA for treatment of mild cognitive impairment or mild dementia due to Alzheimer’s disease in some adults. It is a type of drug called a monoclonal antibody, which is given by infusion (through a drip in the arm).
Surrey Alzheimer's drug trial patient shares his experience of donanemab
Diagnosed with mild cognitive impairment (MCI) in 2018, Mr Almond, from Esher, took part in two 18-month trials for donanemab, receiving his treatment via an intravenous drip once every four weeks at a trial centre in Guildford. Despite undergoing regular MRI and PET scans, he experienced no side effects.
Live news: Second Alzheimer’s drug deemed too expensive for UK’s NHS
Keep abreast of significant corporate, financial and political developments around the world. Stay informed and spot emerging risks and opportunities with independent global reporting, expert commentary and analysis you can trust.
NHS will not fund new drug to slow Alzheimer’s
A new drug that slows the pace of Alzheimer's disease is too expensive for too little benefit to be used on the NHS, the watchdog says.
New Alzheimer’s drugs should be available on NHS, says patient’s wife
New Alzheimer’s drugs should be available on NHS, says patient’s wife - New disease-modifying drugs work best when they are given to patients in the early stages of the disease.
New Alzheimer’s drug rejected for widespread NHS use in England
Donanemab, a pioneering new drug that can treat Alzheimer's, has been rejected by the health spending watchdog.
News Medical on MSN
10h
MHRA greenlights donanemab for early stage Alzheimer’s disease
The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 23 October 2024, approved a license for the ...
1d
on MSN
Tens of thousands to be recruited into Alzheimer’s trials after landmark drug rejected
Tens of thousands of people will be recruited into Alzheimer’s trials after a landmark drug was rejected for use on the NHS.
The Financial Express
1d
Lilly’s donanemab could bring new hope to Alzheimer’s patients in Australia following lecanemab rejection: GlobalData
There are four dementia-specific medications approved in Australia – donepezil, galantamine, rivastigmine, and memantine.
3d
Second ‘game-changing’ Alzheimer’s drug donanemab gets green light in UK – but WON’T be available on NHS
A SECOND “game-changing” Alzheimer’s drug shown to slow the progression of the disease has been approved in the UK. Donanemab, developed by pharmaceutical giant Eli Lilly, was ...
3d
on MSN
UK approves Lilly's Alzheimer's drug, but deemed 'too expensive' for wide use
UK's Medicines and Healthcare products Regulatory Agency (MHRA) approved Eli Lilly's treatment for early Alzheimer's, the ...
Alzheimer's Society
3d
Alzheimer's Society responds to MHRA and NICE announcements on donanemab
The MHRA have approved donanemab for the treatment of Alzheimer’s disease. However, NICE does not recommend use on the NHS ...
2d
Lilly’s Kisunla does not demonstrate “good value” for UK’s NHS
The UK’s National Institute of Health and Care Excellence (NICE) said the drug provided only a small benefit to patients.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Alzheimer
Eli Lilly
lecanemab
United Kingdom
NHS
Feedback